SageView Advisory Group’s Nurix Therapeutics NRIX Stock Holding History

SageView Advisory Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32	Closed	-$608	–	1805
2025 Q4	$608	Buy	+32	New	+$460	﹤0.01%	2430

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

SageView Advisory Group's NRIX Position: Q1 2026 in Review

SageView Advisory Group sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 32 shares — an estimated $608 sold.

SageView Advisory Group first reported a position in NRIX in Q4 2025 and held it in 1 quarter. The position peaked at $608 in Q4 2025. 196 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

SageView Advisory Group reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 32 Nurix Therapeutics shares in Q1 2026, an estimated $608.
SageView Advisory Group first reported a position in Nurix Therapeutics in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Nurix Therapeutics position peaked at $608 in Q4 2025.
196 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.